Cargando…

Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles

CONTEXT: Differentiation between familial chylomicronemia syndrome (FCS, type 1 hyperlipoproteinemia), a rare metabolic disorder, and the more common multifactorial severe hypertriglyceridemia (sHTG, type 5 hyperlipoproteinemia) is challenging because of their overlapping symptoms but important in p...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Dea, Louis St L, MacDougall, James, Alexander, Veronica J, Digenio, Andres, Hubbard, Brant, Arca, Marcello, Moriarty, Patrick M, Kastelein, John J P, Bruckert, Eric, Soran, Handrean, Witztum, Joseph L, Hegele, Robert A, Gaudet, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864364/
https://www.ncbi.nlm.nih.gov/pubmed/31777768
http://dx.doi.org/10.1210/js.2019-00214
_version_ 1783471870188716032
author O’Dea, Louis St L
MacDougall, James
Alexander, Veronica J
Digenio, Andres
Hubbard, Brant
Arca, Marcello
Moriarty, Patrick M
Kastelein, John J P
Bruckert, Eric
Soran, Handrean
Witztum, Joseph L
Hegele, Robert A
Gaudet, Daniel
author_facet O’Dea, Louis St L
MacDougall, James
Alexander, Veronica J
Digenio, Andres
Hubbard, Brant
Arca, Marcello
Moriarty, Patrick M
Kastelein, John J P
Bruckert, Eric
Soran, Handrean
Witztum, Joseph L
Hegele, Robert A
Gaudet, Daniel
author_sort O’Dea, Louis St L
collection PubMed
description CONTEXT: Differentiation between familial chylomicronemia syndrome (FCS, type 1 hyperlipoproteinemia), a rare metabolic disorder, and the more common multifactorial severe hypertriglyceridemia (sHTG, type 5 hyperlipoproteinemia) is challenging because of their overlapping symptoms but important in patient management. OBJECTIVE: To assess whether readily obtainable clinical information beyond triglycerides can effectively diagnose and differentiate patients with FCS from those with sHTG, based on well-curated data from two intervention studies of these conditions. METHODS: The analysis included 154 patients from two phase 3 clinical trials of patients with sHTG, one cohort with genetically confirmed FCS (n = 49) and one with multifactorial sHTG (n = 105). Logistic regression analyses were performed to determine the ability of variables (patient demographics, medical history, and baseline lipids, individually or in sets) to differentiate the patient populations. Receiver operating characteristics were used to determine the variable sets with the highest accuracy (percentage of times actual values matched predicted) and optimal sensitivity and specificity. RESULTS: The primary model diagnosed 45 of 49 patients with FCS and 99 of 105 patients with sHTG correctly. Optimal sensitivity for all available parameters (n = 17) was 91.8%, optimal specificity was 94.3%, and accuracy was 93.5%. Fasting low-density lipoprotein cholesterol (LDL-C) provided the highest individual predictability. However, a three-variable set of ultracentrifugally measured LDL-C, body mass index, and pancreatitis history differentiated the diseases with a near similar accuracy of 91.0%, and adding high-density lipoprotein cholesterol and very low-density lipoprotein cholesterol for a five-variable set provided a small incremental increase in accuracy (92.2%). CONCLUSIONS: In the absence of genetic testing, hypertriglyceridemic patients with FCS and sHTG can be differentiated with a high degree of accuracy by analyzing readily obtainable clinical information.
format Online
Article
Text
id pubmed-6864364
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-68643642019-11-27 Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles O’Dea, Louis St L MacDougall, James Alexander, Veronica J Digenio, Andres Hubbard, Brant Arca, Marcello Moriarty, Patrick M Kastelein, John J P Bruckert, Eric Soran, Handrean Witztum, Joseph L Hegele, Robert A Gaudet, Daniel J Endocr Soc Clinical Research Articles CONTEXT: Differentiation between familial chylomicronemia syndrome (FCS, type 1 hyperlipoproteinemia), a rare metabolic disorder, and the more common multifactorial severe hypertriglyceridemia (sHTG, type 5 hyperlipoproteinemia) is challenging because of their overlapping symptoms but important in patient management. OBJECTIVE: To assess whether readily obtainable clinical information beyond triglycerides can effectively diagnose and differentiate patients with FCS from those with sHTG, based on well-curated data from two intervention studies of these conditions. METHODS: The analysis included 154 patients from two phase 3 clinical trials of patients with sHTG, one cohort with genetically confirmed FCS (n = 49) and one with multifactorial sHTG (n = 105). Logistic regression analyses were performed to determine the ability of variables (patient demographics, medical history, and baseline lipids, individually or in sets) to differentiate the patient populations. Receiver operating characteristics were used to determine the variable sets with the highest accuracy (percentage of times actual values matched predicted) and optimal sensitivity and specificity. RESULTS: The primary model diagnosed 45 of 49 patients with FCS and 99 of 105 patients with sHTG correctly. Optimal sensitivity for all available parameters (n = 17) was 91.8%, optimal specificity was 94.3%, and accuracy was 93.5%. Fasting low-density lipoprotein cholesterol (LDL-C) provided the highest individual predictability. However, a three-variable set of ultracentrifugally measured LDL-C, body mass index, and pancreatitis history differentiated the diseases with a near similar accuracy of 91.0%, and adding high-density lipoprotein cholesterol and very low-density lipoprotein cholesterol for a five-variable set provided a small incremental increase in accuracy (92.2%). CONCLUSIONS: In the absence of genetic testing, hypertriglyceridemic patients with FCS and sHTG can be differentiated with a high degree of accuracy by analyzing readily obtainable clinical information. Endocrine Society 2019-10-11 /pmc/articles/PMC6864364/ /pubmed/31777768 http://dx.doi.org/10.1210/js.2019-00214 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Research Articles
O’Dea, Louis St L
MacDougall, James
Alexander, Veronica J
Digenio, Andres
Hubbard, Brant
Arca, Marcello
Moriarty, Patrick M
Kastelein, John J P
Bruckert, Eric
Soran, Handrean
Witztum, Joseph L
Hegele, Robert A
Gaudet, Daniel
Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles
title Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles
title_full Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles
title_fullStr Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles
title_full_unstemmed Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles
title_short Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles
title_sort differentiating familial chylomicronemia syndrome from multifactorial severe hypertriglyceridemia by clinical profiles
topic Clinical Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864364/
https://www.ncbi.nlm.nih.gov/pubmed/31777768
http://dx.doi.org/10.1210/js.2019-00214
work_keys_str_mv AT odealouisstl differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles
AT macdougalljames differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles
AT alexanderveronicaj differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles
AT digenioandres differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles
AT hubbardbrant differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles
AT arcamarcello differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles
AT moriartypatrickm differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles
AT kasteleinjohnjp differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles
AT bruckerteric differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles
AT soranhandrean differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles
AT witztumjosephl differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles
AT hegeleroberta differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles
AT gaudetdaniel differentiatingfamilialchylomicronemiasyndromefrommultifactorialseverehypertriglyceridemiabyclinicalprofiles